Monitor your progress and results at each level before deciding whether an increase is warranted
its relevance to retatrutide specifically is not yet established A history of pancreatitis or significant gastrointestinal disease Gallbladder disease , including a history of gallstones or cholecystitis Diabetes mellitus , particularly if managed with insulin or sulphonylureas, due to hypoglycaemia risk Cardiovascular disease , including arrhythmias or recent cardiac events Renal or hepatic impairment , which may affect tolerability and increase the risk of dehydration-related complications Pregnancy or breastfeeding no safety data exist for retatrutide in these groups Use of oral medicines where absorption may be affected by delayed gastric emptying , such as levothyroxine or combined oral contraceptives Seek urgent medical attention if you experience severe or persistent nausea or vomiting, persistent abdominal pain (which may indicate pancreatitis or gallbladder disease), signs of an allergic reaction (rash, swelling, difficulty breathing), chest pain, palpitations, or signs of dehydration
No validated beyond-use date can be extrapolated from other GLP-1 receptor agonist medicines such as semaglutide or tirzepatide as stability data are product-specific and cannot be reliably applied across different molecular entities
Stay at your current dose if you are losing 1 to 2 pounds per week, nausea is absent or mild, appetite suppression lasts the full week between injections, and your energy levels are stable
